Evercore ISI initiated coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a note issued to investors on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock.

Separately, Zacks Investment Research cut shares of Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $18.20.

Shares of Myovant Sciences (MYOV) traded down 6.32% during mid-day trading on Wednesday, reaching $9.93. The company had a trading volume of 94,715 shares. The company’s market capitalization is $598.58 million. The company’s 50-day moving average price is $11.28 and its 200-day moving average price is $11.80. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $15.50.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/16/myovant-sciences-ltd-myov-research-coverage-started-at-evercore-isi.html.

Large investors have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP raised its position in Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after buying an additional 3,971 shares during the period. Bank of New York Mellon Corp raised its position in Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares during the period. Wells Fargo & Company MN raised its position in Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in Myovant Sciences during the second quarter valued at about $165,000. Finally, BB Biotech AG raised its position in Myovant Sciences by 0.4% in the second quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock valued at $38,811,000 after buying an additional 14,336 shares during the period.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

The Fly

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.